Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Stage III Prostate Cancer
Stage II Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: abiraterone acetate
Drug: prednisone
Drug: leuprolide acetate
Other: laboratory biomarker analysis
Radiation: external beam radiation therapy
Drug: goserelin acetate

First Posted Date: 2009-12-02

Last Posted Date: 2017-06-06

Lead Sponsor: University of Washington

Target Recruit Count: 24

Registration Number: NCT01023061

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Neoplasms

Interventions: Drug: Abiraterone acetate
Drug: Prednisone
Drug: Theophylline
Drug: Dextromethorphan hydrobromide

First Posted Date: 2009-11-23

Last Posted Date: 2013-04-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT01017939

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Phase 2

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin

First Posted Date: 2009-11-09

Last Posted Date: 2011-10-13

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 50

Registration Number: NCT01009970

Locations: 🇮🇹
Ospedale Sant'Eugenio, Roma, Italy
🇮🇹
Ospedale Riuniti, Trieste, Italy
🇮🇹
Ospedale SS Antonio Biagio e Cesare Arrigo, Alessandria, Italy

and more 29 locations

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Conditions: Leukemia

First Posted Date: 2009-11-01

Last Posted Date: 2014-01-10

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 180

Registration Number: NCT01005758

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: vincristine
Drug: doxorubicin
Drug: prednisone
Drug: azacytidine

First Posted Date: 2009-10-30

Last Posted Date: 2017-04-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 14

Registration Number: NCT01004991

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Alloantibodies in Pediatric Heart Transplantation

Terminated

Conditions: Pediatric Heart Transplantation
Pediatric Heart Transplant Recipients

Interventions: Drug: Induction Therapy
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Procedure: Intraoperative plasma exchange/pheresis
Procedure: Short-term post-operative plasmapheresis
Drug: Immunoglobulins, Intravenous
Drug: Prednisone

First Posted Date: 2009-10-30

Last Posted Date: 2017-04-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 290

Registration Number: NCT01005316

Locations: 🇺🇸
Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital at Montefiore, Bronx, New York, United States

and more 5 locations

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Phase 1

Completed

Conditions: Leukemia-Lymphoma, Adult T-Cell

Interventions: Drug: Bortezomib
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Raltegravir

First Posted Date: 2009-10-23

Last Posted Date: 2017-03-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT01000285

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Miami Hospital/Sylvester, Miami, Florida, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 3 locations

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Bevacizumab
Drug: Erlotinib
Drug: Prednisone

First Posted Date: 2009-10-16

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 4

Registration Number: NCT00996502

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

Phase 3

Terminated

Conditions: Ocular Myasthenia Gravis

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2009-10-15

Last Posted Date: 2017-06-02

Lead Sponsor: Michael Benatar

Target Recruit Count: 11

Registration Number: NCT00995722

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Vermont, Burlington, Vermont, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

and more 7 locations

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Phase 3

Terminated

Conditions: Immune Thrombocytopenic Purpura

Interventions: Drug: Dexamethasone USP Micronized
Drug: Prednisone

First Posted Date: 2009-10-08

Last Posted Date: 2014-02-14

Lead Sponsor: Carelon Research

Target Recruit Count: 8

Registration Number: NCT00991939

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy